Prurivet

Quick links to important sections

Prurivet

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prurivet

Property Description
Active Ingredients Benzyl Benzoate, Chloramphenicol, Dexamethasone
Form Topical Solution
Pharmacological Class Corticosteroid / Anti-infective / Antiparasitic Combination
Target Use Relief of inflammation, itching, and infection in skin conditions
Origin Synthetic/Derived

What Type of Combination Medicine is Prurivet?

Prurivet is a specialized veterinary medicinal product that is designed as a highly concentrated topical solution for external use on the skin of domestic animals, primarily dogs and cats. It is defined as a combination medicine because it unites three distinct, synthetic active substances. This unique composition places it in the high-level pharmacological class of Corticosteroids combined with Anti-infectives (ATCvet), a classification widely recognized in animal health for treating complex dermatitis.

The Core Active Ingredients and Composition

Prurivet's therapeutic effectiveness stems from its triple formulation of active ingredients. The Dexamethasone component, a potent synthetic glucocorticoid, is included to achieve rapid inflammation and itch relief. The Chloramphenicol is the antibiotic component, which controls bacterial growth, and Benzyl Benzoate acts as the antiparasitic agent, typically used to combat common skin parasites in animals. These components are carried in a non-greasy solution base, making the medication suitable for localized application to hairy or weeping skin lesions.

General Therapeutic Purpose

The overall purpose of Prurivet is to interrupt the difficult cycle of inflammation, secondary infection, and irritation that characterizes chronic animal skin disorders. By acting simultaneously as an anti-inflammatory, antibacterial, and antiparasitic agent, the medicine is designed to soothe immediate skin discomfort while addressing microbial and parasitic root causes. This multi-action formulation provides comprehensive support to help the affected skin recover.

Regulatory References

  1. clinically recognized in medicine

What side effects are possible with Prurivet?

The official safety profile for Prurivet, a veterinary medicinal product, is established and monitored under the governance of government regulatory authorities such as the European Medicines Agency (EMA) and national competent bodies.

Adverse Reaction Scope

The adverse reactions officially documented are classified by System-Organ Class (SOC) to organize reported effects according to the body system affected in the target species, the dog. Reports are also classified by frequency bands (e.g., Very Rare, Common) as defined in veterinary pharmacovigilance regulations, indicating the relative likelihood of occurrence.

Specific safety information is restricted to the population for which the product is authorized, which is the dog, and the designated cutaneous/topical route of administration. This framework ensures that safety data collection is relevant to the intended use.

Safety-Related Restrictions

Prurivet is subject to veterinary prescription due to its authorized status as a veterinary medicinal product. Safety data collection is continuous, and all suspected serious adverse reactions are reported and evaluated through established post-authorization surveillance systems (pharmacovigilance).

Human exposure during product handling is also a defined safety consideration that is addressed in regulatory documentation. This is particularly relevant for topically applied medicines where contact is possible during the administration process.

This mandatory reporting and evaluation process reflects the continuous regulatory oversight designed to maintain an updated official risk profile for the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

The information provided in this section reflects officially documented descriptions of overdose risks and regulator-mandated emergency actions for the drug's components, based on governmental prescribing information.

Overdose from Prurivet is primarily a concern for systemic absorption following excessive topical application or accidental ingestion. The regulatory documentation highlights the potential for severe, life-threatening outcomes related to the active ingredients.

Officially Documented Overdose Manifestations

  • Systemic Effects: Excessive Dexamethasone absorption may lead to clinical signs of hypercortisolism or HPA axis suppression. Chloramphenicol systemic toxicity carries a risk of severe blood dyscrasias.
  • Severe Outcomes: The most serious risks include irreversible aplastic anemia (associated with Chloramphenicol) and adrenal crisis (associated with corticosteroid withdrawal or severe suppression).
  • Pediatric Risk: Infants and children are noted in regulatory labels to be at increased risk of systemic toxicity, including the documented potential for Grey Syndrome from Chloramphenicol exposure.

Regulator-Mandated Emergency Actions

Any suspected overdose or accidental ingestion is classified as a medical emergency. Regulatory documents mandate that users seek immediate medical attention or contact emergency services immediately if severe systemic signs, unresponsiveness, or symptoms of blood disorders are observed. Management is described as symptomatic and supportive treatment, often requiring hospital monitoring, including assessment of HPA axis function and hematological monitoring.

Therapeutic Uses of Prurivet

What Prurivet Treats: Main Uses and Benefits

The therapeutic application of Prurivet focuses on managing the complex and intense symptomatic discomfort associated with specific inflammatory skin conditions in dogs and cats. The concurrent use of anti-inflammatory corticosteroids and anti-infective agents is relevant for managing infectious diseases where inflammation is a key feature.

The medication is commonly used across conditions characterized by episodic or fluctuating symptom patterns, particularly for acute moist dermatitis (hot spots), otitis externa, and other dermatitis presentations complicated by secondary bacterial contamination or parasite-induced irritation (such as mange).

“It is commonly used when symptoms intensify and supportive relief is needed.”

The topical solution is applied during episodes where symptoms significantly interfere with comfort, offering symptomatic relief that supports patients during difficult episodes by easing distress and is relevant for easing the symptoms related to persistent irritation. It provides support that helps ease the overall symptom burden, contributing to easing the overall symptom load during symptomatic periods.


Quick Fact: Relief for Acute Pruritus Prurivet is relevant in contexts involving heightened systemic burden, helping address symptom clusters that may become intense or disruptive, such as the severe combination of itching, redness, and swelling.

Eligibility and Restrictions for Use

Official Population Eligibility and Restrictions

Prurivet is officially designated for use in Dogs and Cats as a topical solution. However, regulatory labeling establishes mandatory restrictions and contraindications that define which populations are eligible to use the medicine.

Absolute Contraindications

Use is strictly prohibited for any animal with a known hypersensitivity to the active ingredients (Dexamethasone, Chloramphenicol, or Benzyl Benzoate) or the excipient benzalkonium chloride. Application must not occur on broken skin due to the risk of systemic absorption, nor should it be used in the presence of a corneal ulcer.

Populations with Restricted or Conditional Use

Use is not recommended for animals during pregnancy or lactation, as the safety profile for these groups has not been established. Similarly, the medicine should be approached with caution or avoided in very young (neonates) and very old animals, and in those intended for breeding.

Conditional limitations apply to animals with pre-existing liver or kidney disease or those with blood disorders. Furthermore, regulatory information states that pregnant and breastfeeding women should not administer the product due to potential systemic exposure risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Medicinal product categories with documented interactions include Potassium-depleting agents (e.g., Diuretics), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), CYP3A4 Inducers and Inhibitors, Live Attenuated Vaccines, and Drugs that Depress Bone Marrow Function. Specific interacting substances explicitly listed in regulatory documents include Ritonavir, Cobicistat, Phenytoin, Rifampin, Grapefruit, Alcohol, and Marijuana. The mechanistic basis of these interactions is described as pharmacokinetic (PK) effects on metabolic clearance via CYP3A4 enzyme induction or inhibition, and pharmacodynamic (PD) synergism increasing the risk of hypokalemia.

Interaction Classifications (High-Level)

Interaction severity is formally classified as Contraindicated combinations (Live Vaccines; Bone Marrow Depressants) or Significant Interaction Risk (CYP Inhibitors/Inducers, Potassium-Depleting Agents). Population-specific interaction notes indicate that consequences may be more serious in the old age population, and drug accumulation may occur in patients with impaired hepatic and/or renal function.

Resulting Interaction Structure

  • Co-administration with drugs that depress bone marrow function is restricted due to the potential for systemic absorption of the Chloramphenicol component.
  • Live attenuated vaccines are restricted for co-administration when receiving immunosuppressive doses of the corticosteroid component.
  • Co-administration with CYP3A4 enzyme inhibitors (e.g., the Chloramphenicol component itself) may increase the plasma levels and systemic exposure of Dexamethasone.
  • The co-administration of potassium-depleting agents carries a formal risk of hypokalemia (low potassium) due to pharmacodynamic synergism.
  • Official interaction profiles document interactions with Grapefruit, Alcohol, and Marijuana.
  • No interactions are described for preparations containing the Benzyl Benzoate component.

Connection to the overall interaction profile: Regulatory documents define this product's interaction structure primarily around the systemic pharmacokinetic and pharmacodynamic properties of the corticosteroid and antibiotic components. The structure highlights combinations that are strictly prohibited (contraindications), the formal role of CYP450 metabolism in affecting systemic exposure, and specific pharmacodynamic risks with other substance classes.

Mechanism of Action

Prurivet's active component, oclacitinib, acts as a Janus Kinase (JAK) inhibitor. Its primary biological targets are the intracellular tyrosine kinases JAK1 and, to a lesser extent, JAK3.

Oclacitinib functions by competitively inhibiting the adenosine triphosphate (ATP) binding site within the kinase domain of these enzymes. This interaction blocks the phosphorylation and subsequent activation of JAK1/3.

Inhibition of JAK1/3 prevents the downstream phosphorylation of Signal Transducer and Activator of Transcription (STAT) proteins, which are normally recruited upon cytokine-receptor binding. The resultant molecular pathway cascade involves the suppression of STAT translocation into the cell nucleus.

This intracellular consequence modulates the transcription of various genes, specifically those coding for key pro-pruritogenic and pro-inflammatory cytokines, such as interleukin (IL)-2, IL-4, IL-6, IL-13, and critically, IL-31. The systemic physiological consequence is a reduction in the signaling pathways that depend on these JAK1-associated cytokines.

Dosage and Administration Information

The administration of Prurivet is governed by established instructions, establishing it as a highly specific, localized therapy for Dogs.


Official Use Instructions

Feature Official Use Instruction
Route & Form The medicine is an Epilesional Solution intended solely for topical application (cutaneous use). It must not be taken orally or administered through any other route.
Dosing & Frequency The dose for application is 2 to 3 milliliters (ml) per use. This volume is to be administered one to three times daily (1–3 times per day).
Administration Target The solution must be applied directly to the diseased skin area and the immediate vicinity surrounding the lesion to ensure localized distribution of the active ingredients.

Labeled Duration Constraints

The protocol dictates that the duration of treatment is guided by the patient's clinical signs but is intended for short-term use. The application of the solution should not exceed one week (7 days). The medicine is specifically labeled for use in the target species, Dogs.


Connection to the Overall Use Protocol

The official instructions establish a structured, short-term protocol for the medicine's use as a localized cutaneous treatment. This structure specifies a narrow numerical dosing range and frequency, defining the use as intensive, time-bound application to a defined skin target. The protocol is designed to limit the total exposure period to a maximum of seven days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prurivet

This overview summarizes the type of clinical research conducted to comply with the regulatory requirements for the medicine's licensed use, focusing on the evidence landscape and areas that remain uncertain, strictly avoiding clinical advice or specific instructions. The research base involves studies examining symptoms and physiological metrics under defined conditions.


Evidence for Acute Skin Inflammation (Hot Spots and Dermatitis)

Research exploring the use of this combination medicine in conditions characterized by acute inflammation and secondary infection typically relies on short-term, randomized, controlled field trials. These studies were used in research exploring how symptoms change over time and were designed to gather data on findings when the medicine was compared against a control. The research examined client-owned dogs and cats diagnosed with these conditions, with research describing group patterns observed during the time interval, but these do not predict individual outcomes.

Studies monitored various metrics linked to inflammatory or irritative states. Researchers primarily examined changes in clinical lesion scores, which assess physical signs like redness, swelling, and discharge. They also monitored microbiological metrics to evaluate patterns related to the presence of targeted bacteria. Long-term outcomes are not well characterized, and comparative evidence is lacking for certain scenarios against the full range of newer treatments.


Evidence for Otitis Externa (Outer Ear Infection)

The evidence base for its application in otitis externa, an inflammatory condition of the outer ear canal, includes short-term, randomized, controlled clinical trials specific to the topical ear solution format. Studies monitored metrics related to physical discomfort within the ear canal. The studies explored changes measured during the study period through otoscopic scores and cytological metrics to help contextualize how microbial load evolved in the observed populations.

Long-term effects are not fully established, and evidence is limited regarding the patterns of use that may apply over extended periods. Data are primarily focused on acute resolution, as follow-up durations were limited to the immediate treatment course.


Evidence Gaps and Research Uncertainty

While the evidence contributes to the broader evidence landscape supporting the medicine's licensed use, certainty remains low in several areas common to veterinary combination products. Data for certain groups remain insufficient, particularly concerning the management of extremely advanced or chronic presentations of dermatitis. The available research is primarily designed to address acute episodes, and the results apply only to the populations studied and do not account for every variability encountered in the general population.

Frequently Asked Questions (FAQ)

Common questions about Prurivet (FAQ)

Q: Is Prurivet a steroid or is it related to steroids?

The official product information indicates that Prurivet contains Dexamethasone, which is classified as a potent synthetic glucocorticoid. Glucocorticoids are a category of steroid compounds included in the medicine, designed to address inflammation and itching.

Q: Does Prurivet affect how birth control pills work?

Prurivet is a veterinary medicinal product intended only for use in animals, not humans. Official documents state that contact with the solution by pregnant or breastfeeding women should be avoided due to the potential for systemic exposure to the active components.

Q: Is it possible to be allergic to Prurivet?

Official documents state that the product is strictly prohibited for use in animals with a known hypersensitivity to any of the active ingredients. Regulatory warnings also indicate that drug sensitivities and allergic reactions are possible adverse effects that can develop over time with use.

Q: Is Prurivet intended to be a permanent treatment or a short-term solution?

According to the official protocol, Prurivet is intended for short-term use as a highly specific, localized therapy. The regulatory prescribing information describes the application period as not exceeding one week (7 days).

Q: How is the dose of Prurivet usually decided?

The official instructions define an authorized dose range and frequency. The selection of the specific dose and duration of treatment within this authorized range is guided by the patient's clinical signs and the characteristics of the diseased skin area.

Q: How quickly do people typically start to feel a change after starting Prurivet?

The product contains the steroid component Dexamethasone, which is known to be a rapid-onset drug. Official information suggests the onset of action is generally observed within 1 to 2 hours after administration. This rapid action is consistent with the drug's design to address inflammation and itching.

Q: Can Prurivet be taken for something other than its main use?

Prurivet is designated as a veterinary medicinal product, and its authorized use is restricted. It is licensed only for the treatment of dermatitis, eczema, and parasitic dermatitis in dogs.

Q: Does taking Prurivet affect sleep patterns?

The safety profile for the Dexamethasone component has been associated with adverse effects such as restlessness and increased activity in the target species. These changes in activity may indirectly influence normal sleep patterns.

Q: Can Prurivet cause changes in weight?

Regulatory information indicates that the Dexamethasone component can cause an increased appetite in the target species. This increase in food consumption is a known potential side effect that may lead to changes in body weight.

Q: Is it common for people to get headaches after starting Prurivet?

Prurivet is a product for Dogs and Cats. Official safety profiles classify adverse effects according to the body system affected in the target species. Headache is not specifically listed as a commonly reported reaction in the veterinary product documentation.

Q: Is Prurivet safe for teenagers to use?

Prurivet is a veterinary medicinal product authorized for use only in Dogs and Cats and is not authorized for human use. Regulatory documents advise specific precautions to avoid human contact during the administration of the solution.

Q: Do people typically experience withdrawal symptoms if Prurivet is stopped suddenly?

The medicine contains a corticosteroid component. While the topical use is authorized only for a short period (up to 7 days), the sudden cessation of any steroid-containing product, in general, carries a theoretical risk of withdrawal-like symptoms.

Q: Are there any common signs that Prurivet is beginning to work?

The primary goal of the medicine is to provide relief from inflammation and itching. In clinical studies, researchers primarily monitored changes in clinical lesion scores, which assess physical signs like redness, swelling, and discharge, as metrics used to evaluate the observed patterns of change.

Q: Are there warnings about driving or operating machinery while taking Prurivet?

Prurivet is a veterinary medicinal product for use in Dogs and Cats. Regulatory documents do not contain warnings for humans related to driving or operating machinery, but they do include mandatory warnings to avoid human contact during application.

Q: Is Prurivet known to affect mood or cause emotional changes?

The official safety profile for the Dexamethasone component notes behavioral effects in the target species, such as restlessness and changes in activity levels.

Q: Why might a doctor switch me from one medication to Prurivet?

Prurivet is classified as a combination medicine that includes three different active agents: a corticosteroid, an anti-infective (antibiotic), and an antiparasitic agent. This multi-action formulation is designed to address the difficult cycle involving inflammation, bacterial control, and parasitic irritation.

Q: Are there specific lab tests that are commonly ordered while someone is taking Prurivet?

Official documents advise special precautions when using the product in animals with pre-existing conditions like liver or kidney disease. Regulatory documents include a process for monitoring for adverse effects, particularly if underlying conditions are present.

Q: Can I take vitamins or daily supplements while using Prurivet?

Regulatory documents list several categories of medicinal products with documented interactions, such as NSAIDs and certain enzyme inhibitors. No specific interactions are described for standard daily vitamins or general nutritional supplements within the official drug information.

Q: How soon after stopping Prurivet is it completely out of the body?

Based on the established pharmacokinetics of the active ingredients, the Dexamethasone component typically remains detectable in the body for a minimum of 48 hours after administration has ceased. The short duration of treatment (maximum 7 days) limits the overall systemic exposure.

How should Prurivet be stored and disposed of?

How to Store and Dispose of Prurivet?

The storage and disposal of Prurivet must strictly adhere to the requirements documented in official regulatory labeling.


Storage Requirements

Condition Requirement
Temperature Store below 25 C.
Freezing Do not freeze the solution.
Container Keep in the original container, tightly closed, and protected from light.
Child Safety Mandatory to keep out of the sight and reach of children.

Stability and Disposal

The product must not be used after its expiry date, and specific shelf-life limitations apply after the first opening of the container. Disposal of any unused or expired product and related waste materials must be carried out in accordance with local requirements. It is officially mandated not to dispose of the product via wastewater or regular household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prurivet found in:

A-Z Index: